The University of Texas MD Anderson Cancer Center and Sibylla Biotech announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders, which disrupt the proper folding of target proteins and lead to their degradation.
Jeffrey E. Lee was appointed chief medical executive at The University of Texas MD Anderson Cancer Center, effective April 1.
